Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest update is out from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( (HK:1276) ).
Jiangsu Hengrui Pharmaceuticals Co., Ltd. has announced the convening of its 2025 first extraordinary shareholders’ meeting to discuss and approve the adoption of the 2025 A Share Employee Stock Ownership Scheme and its administrative measures. The meeting will also address the authorization for the board of directors to manage related matters and the appointment of Ernst & Young as the company’s international auditor. These resolutions are expected to enhance employee engagement and ensure robust financial auditing, potentially strengthening the company’s market position and operational transparency.
The most recent analyst rating on (HK:1276) stock is a Buy with a HK$80.57 price target. To see the full list of analyst forecasts on Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H stock, see the HK:1276 Stock Forecast page.
More about Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H
Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a pharmaceutical company based in China, primarily engaged in the research, development, manufacturing, and distribution of a wide range of pharmaceutical products. The company focuses on providing innovative and high-quality medical solutions to meet the needs of patients and healthcare providers globally.
Average Trading Volume: 4,737,589
Current Market Cap: HK$478.9B
For an in-depth examination of 1276 stock, go to TipRanks’ Overview page.